Article Details
Retrieved on: 2018-01-31 23:56:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>Paul's earlier experience includes serving as a venture partner at <b>Third Rock</b> <b>Ventures</b> as well as a 17-year run at Eli Lilly (NYSE: LLY). Voyager's lead drug candidate is an experimental gene therapy for Parkinson's disease. The company is developing the treatment VY-AADC01 without partner Sanofi ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here